A61K 31/4738
Ortho- or peri-condensed with heterocyclic ring systems
Official title: ortho- or peri-condensed with heterocyclic ring systems
A61K31/4738 (Ortho- or peri-condensed with heterocyclic ring systems) appears on 3,101 US grants and 6,216 published applications in this corpus.
Search patents in A61K- Granted patents
- 3,101
- Published applications
- 6,216
- Assignees
- 2,072
- Inventors
- 10,687
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 3 | 0 |
| 1996 | 6 | 0 |
| 1997 | 26 | 0 |
| 1998 | 20 | 0 |
| 1999 | 29 | 0 |
| 2000 | 25 | 0 |
| 2001 | 34 | 9 |
| 2002 | 39 | 121 |
| 2003 | 69 | 171 |
| 2004 | 59 | 205 |
| 2005 | 51 | 233 |
| 2006 | 50 | 292 |
| 2007 | 59 | 260 |
| 2008 | 53 | 136 |
| 2009 | 49 | 143 |
| 2010 | 78 | 202 |
| 2011 | 109 | 177 |
| 2012 | 85 | 157 |
| 2013 | 106 | 204 |
| 2014 | 141 | 261 |
| 2015 | 159 | 309 |
| 2016 | 181 | 364 |
| 2017 | 188 | 325 |
| 2018 | 224 | 292 |
| 2019 | 206 | 333 |
| 2020 | 204 | 309 |
| 2021 | 190 | 317 |
| 2022 | 172 | 295 |
| 2023 | 129 | 298 |
| 2024 | 121 | 322 |
| 2025 | 148 | 261 |
| 2026 | 84 | 220 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Method of treating SCLC and managing neutropenia29 Sep 2026US 12,746,240 B2Pharma Mar, S. A.
- Nitrogen-containing heterocyclic compound having MYT1 inhibitory activity29 Sep 2026US 12,747,239 B2Chugai Seiyaku Kabushiki Kaisha
- Camptothecin derivatives29 Sep 2026US 12,747,250 B2ImmunoGen, Inc.
- TLR7/8 antagonists and uses thereof22 Sep 2026US 12,740,978 B2Merck Patent GmbH
- Anti-CLDN18.2 antibody, drug conjugate, and preparation method therefor and use thereof22 Sep 2026US 12,741,032 B2Cspc Megalith Biopharmaceutical Co., Ltd.
- Modified liposome for drug delivery, use of liposome for drug delivery, especially with anti-cancer activity, and ways to load liposome with drugs, especially with anti-cancer activity8 Oct 2026US 2026/0306403 A1Bs Biotechna Spolka Akcyjna
- Inhaled statins as bronchodilators to improve lung function in respiratory diseases8 Oct 2026US 2026/0306477 A1Beth Israel Deaconess Medical Center, Inc.
- Nanoparticles for photoimmune therapy comprising photosensitizer and adjuvant, and usage thereof8 Oct 2026US 2026/0306632 A1Korea Institute of Science and Technology
- Deuterated camptothecin compound, and preparation therefor and use thereof8 Oct 2026US 2026/0308167 A1Shanghai Qilu Pharmaceutical Research and Development Centre Ltd.
- Novel ras inhibitors1 Oct 2026US 2026/0294893 A1
Most cited
By later US patents
- Controlled local delivery of chemotherapeutic agents for treating solid tumors349US 5,626,862 AMassachusetts Institute of Technology · 1997
- Immune response modifier compounds for treatment of TH2 mediated and related diseases285US 6,039,969 A3M Innovative Properties Company · 2000
- Formulations and methods for treatment of mucosal associated conditions with an immune response modifier272US 6,245,776 B13M Innovative Properties Company · 2001
- Imidazonaphthyridines255US 6,194,425 B13M Innovative Properties Company · 2001
- Sulfonamide and sulfamide substituted imidazoquinolines255US 6,331,539 B13M Innovative Properties Company · 2001